2nd Circ. Considers Reinstating Fosamax Witness
A federal appeals court panel has questioned the value of reinstating a doctor's "equivocal" testimony in a bellwether case in product liability multdistrict litigation over Merck & Co. Inc.'s osteoporosis drug...To view the full article, register now.
Already a subscriber? Click here to view full article